Reaction Details Report a problem with these data
Target
Galectin-3
Ligand
BDBM468290
Substrate
n/a
Meas. Tech.
Evaluation of Kd Values
Kd
1.000±n/a nM
Citation
 Leffler, H; Nilsson, U; Zetterberg, F Hybrid galactoside inhibitor of galectins US Patent  US10800804 Publication Date 10/13/2020 
Target
Name:
Galectin-3
Synonyms:
LEG3_HUMAN | LGALS3 | MAC2
Type:
Enzyme
Mol. Mass.:
26156.54
Organism:
Homo sapiens (Human)
Description:
P17931
Residue:
250
Sequence:
MADNFSLHDALSGSGNPNPQGWPGAWGNQPAGAGGYPGASYPGAYPGQAPPGAYPGQAPPGAYPGAPGAYPGAPAPGVYPGPPSGPGAYPSSGQPSATGAYPATGPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI
  
Inhibitor
Name:
BDBM468290
Synonyms:
3-{4-[(Butylamino)carbonyl]-1H-1,2,3-triazol-1-yl}-3,3′-dideoxy-3′-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-1,1′-sulfanediyl-di-β-D-galactopyranoside | US10800804, Example S11
Type:
Small organic molecule
Emp. Form.:
C27H34F3N7O9S
Mol. Mass.:
689.661
SMILES:
CCCCNC(=O)c1cn(nn1)C1C(O)[C@@H](CO)OC(S[C@@H]2OC(CO)[C@H](O)[C@@H](C2O)n2cc(nn2)-c2cc(F)c(F)c(F)c2)[C@@H]1O |r|
Structure:
Search PDB for entries with ligand similarity: